Developer docs
API playgroundTry for free, no card

Search company profiles

Q32 Bio

Full company profile

uuid00009ho

Namestring
Q32 Bio
Legal namestring
Q32 Bio Inc.
Websiteurl
q32bio.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Q32 Bio is a clinical-stage biotechnology company developing therapeutics for patients with severe autoimmune and inflammatory diseases, headquartered in Waltham, Massachusetts. The company's lead clinical asset is bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody designed to re-regulate adaptive immune function by simultaneously blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling through their shared receptor. Bempikibart is currently being evaluated in the SIGNAL-AA Phase 2a trial for severe or very severe alopecia areata and has received FDA Fast Track Designation for that indication. The company also maintains a tissue-targeted complement inhibition platform built around ADX-096 (a C3d–CR1 fusion protein) and earlier-stage C3d monoclonal antibody fusions and nanobodies, designed to localize complement inhibition to diseased tissue while preserving other complement functions. In December 2025, Q32 Bio divested its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million upfront plus up to $592 million in potential milestones and tiered royalties, refocusing resources on bempikibart.

Q32 Bio is publicly traded on Nasdaq (ticker: QTTB) following a March 2024 reverse merger with Homology Medicines and a concurrent $42 million private placement. The company is pre-revenue, with no approved products, and funds operations entirely through equity capital markets — having raised approximately $79.5 million in 2026 across a $10.5 million registered direct offering, $14.2 million and up to $75 million ATM programs with Cantor Fitzgerald, and a $55 million private placement led by BVF Partners L.P. with participation from RA Capital Management, OrbiMed, and Atlas Venture. Q1 2026 net loss was $7.6 million (reduced from $11.0 million in the prior-year period), and cash runway has been extended into 1H 2028. The company is led by CEO Jodie Morrison (former CEO of Cadent Therapeutics), CSO/President of Research Shelia Violette (Ph.D., ex-VP Research at Biogen), and President & CFO Lee Kalowski (former CFO of Bicycle Therapeutics). Future commercialization is expected to be enabled via out-licensing and strategic partnerships with larger pharmaceutical companies, as demonstrated by the Akebia transaction.

Short descriptiontext

Q32 Bio is a clinical-stage biotechnology company developing bempikibart, an anti-IL-7Rα monoclonal antibody in Phase 2a for severe alopecia areata, plus a tissue-targeted complement inhibition platform for patients with autoimmune and inflammatory diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, autoimmune disease therapeutics, monoclonal antibody development, complement inhibition platform, inflammatory disease treatments
Industry2 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biologics for Autoimmune Diseases
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Out-licensing and asset divestiture
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotech monetizing non-core assets via out-licensing/divestiture. Sold Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million upfront plus near-term milestone payments, up to $592 million in potential milestone payments, and tiered royalties. No product revenue is generated as bempikibart remains in clinical development.

prnewswire.com
2Equity / capital markets financing
TypeLicensing Royalties
Description

Repeated capital raises via registered direct offerings, private placements, and at-the-market (ATM) equity programs to fund clinical development. 2024-2026 financings include a $42M private placement (with Homology merger), $10.5M direct offering, $14.2M ATM, and $55M private placement.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Q32 Bio is a clinical-stage biotechnology company developing biologic therapies that rebalance the immune system in patients with severe autoimmune and inflammatory diseases. Its lead candidate, bempikibart (ADX-914), is a fully human anti–IL-7Rα monoclonal antibody currently in the SIGNAL-AA Phase 2a trial for severe or very severe alopecia areata, supported by FDA Fast Track Designation. The company also operates a tissue-targeted complement inhibition platform anchored by C3d–CR1 fusion proteins and nanobodies, with development candidate ADX-096.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • SIGNAL-AA Phase 2a Part B enrolled 33 patients, exceeding the initial target of 20 patients
+4 more records
Product overview1 text field

Q32 Bio is a clinical-stage biotechnology company with a focused, single-platform therapeutic portfolio rather than a software-style platform-plus-modules architecture. Its lead clinical asset, bempikibart (ADX-914), is a fully human anti-IL-7Rα monoclonal antibody that anchors the company's IL-7/TSLP program, currently in the SIGNAL-AA Phase 2a trial for severe or very severe alopecia areata. Complementing this is the Complement Inhibitor Platform — a tissue-targeted complement modulation platform built around the development candidate ADX-096 (a C3d–CR1 fusion protein) plus earlier-stage C3d mAb fusions and nanobodies, with the previously advanced ADX-097 divested to Akebia Therapeutics in 2025. Together, the IL-7/TSLP Program and the Complement Inhibitor Platform form the entirety of Q32 Bio's disclosed product offering, all aimed at restoring immune homeostasis in patients with severe inflammatory and autoimmune diseases.

Product and service3 records
1Bempikibart (ADX-914)
CategoryLead product candidate (clinical-stage biologic)
Description

Bempikibart (ADX-914) is a fully human anti–interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling through their shared receptor. It is Q32 Bio's most advanced product candidate, currently in the SIGNAL-AA Phase 2a trial in patients with severe or very severe alopecia areata, and has received FDA Fast Track Designation for alopecia areata.

2ADX-096
CategoryComplement inhibitor development candidate
Description

ADX-096 is a C3d–CR1 fusion protein and lead asset of Q32 Bio's tissue-targeted complement inhibitor platform. It is designed to deliver complement inhibition directly to diseased tissue while leaving other complement functions largely unimpaired, addressing complement-mediated diseases across kidney, skin, blood, lung, neuromuscular junction, and brain indications.

3IL-7/TSLP Program
CategoryTherapeutic program
Description

The IL-7/TSLP program is Q32 Bio's research and clinical effort targeting dysfunctional regulation of the adaptive immune system by blocking IL-7 and TSLP signaling. Its lead clinical asset is bempikibart (ADX-914); the program is being evaluated in alopecia areata and explored for additional autoimmune and inflammatory indications where IL-7 and/or TSLP pathways drive disease.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-22
Description

Q32 Bio amended its agreement with Amgen to eliminate $75.1 million in remaining regulatory and sales milestone obligations, removing a material contingent liability from the company's balance sheet.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, receiving $12 million upfront plus additional near-term milestone payments, up to $592 million in potential milestone payments, and tiered royalties. The transaction funds Q32 Bio's operations into 2027 and allows it to focus resources on bempikibart for alopecia areata.

3Bristol Myers Squibb
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

Bristol Myers Squibb is the originator from which Q32 Bio licensed bempikibart. Q32 Bio retained global rights to develop and commercialize the asset, including the ongoing SIGNAL-AA Phase 2a program.

in.investing.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Concert Pharmaceuticals
TypeDirect peer
Description

Clinical-stage biotech developing treatments for alopecia areata, including deuruxolitinib (a JAK inhibitor). Highly comparable as a similarly sized, single-indication-focused biotech pursuing severe alopecia areata with a novel mechanism.

TypeDirect peer
Description

Clinical-stage immunology-focused biotech developing therapies for alopecia areata and other inflammatory skin diseases. Directly comparable in target indication, development stage, and small-cap biotech profile.

3Horizon Therapeutics
TypeBroad incumbent
Description

Large immunology-focused biotech (now part of Amgen) that was previously partnered with Q32 Bio on bempikibart's Phase 2 study in atopic dermatitis. Comparable as a developer of immunology biologics with overlapping autoimmune disease focus.

TypeEmerging player
Description

Biotech that acquired Q32 Bio's ADX-097 complement inhibitor and is developing it for complement-mediated diseases including renal diseases. Directly comparable as a small-cap clinical-stage biotech working in the complement pathway space.

TypeDirect peer
Description

Clinical-stage biotech developing antibodies targeting inflammatory and autoimmune pathways, including IL-36R antagonists. Comparable in therapeutic area (autoimmune/inflammatory biologics), clinical stage, and small-cap profile.

TypeEmerging player
Description

Clinical-stage biotech developing novel biologics for atopic dermatitis and other inflammatory diseases. Comparable as a recently public small-cap immunology biotech pursuing autoimmune indications with biologic modalities.

7Dice Therapeutics
TypeEmerging player
Description

Clinical-stage biotech developing oral IL-17 inhibitors for autoimmune diseases (acquired by Eli Lilly in 2024). Comparable in therapeutic area, modality innovation, and clinical-stage development focus.

TypeEmerging player
Description

Clinical-stage biotech developing cell therapies for autoimmune diseases. Comparable as a small-cap clinical-stage immunology biotech with novel therapeutic modalities targeting autoimmune pathways.

TypeEmerging player
Description

Clinical-stage biotech developing monoclonal antibodies for autoimmune diseases, including FcRn inhibitors. Comparable as a small/mid-cap clinical-stage immunology biotech with similar investor base (RA Capital, BVF, Atlas Venture participated in financings).

10Bristol Myers Squibb
TypeOthers
Description

Original licensor of bempikibart to Q32 Bio, retaining milestone/royalty rights. As a major pharma with JAK inhibitors and immunology franchises, BMS is both an asset licensor and a potential competitor/acquirer, making it a structural reference point.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Q32 Bio

Biologics for Autoimmune Diseasesq32bio.com

Q32 Bio is a clinical-stage biotechnology company developing bempikibart, an anti-IL-7Rα monoclonal antibody in Phase 2a for severe alopecia areata, plus a tissue-targeted complement inhibition platform for patients with autoimmune and inflammatory diseases.

What Q32 Bio does

Q32 Bio is a clinical-stage biotechnology company developing therapeutics for patients with severe autoimmune and inflammatory diseases, headquartered in Waltham, Massachusetts. The company's lead clinical asset is bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody designed to re-regulate adaptive immune function by simultaneously blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling through their shared receptor. Bempikibart is currently being evaluated in the SIGNAL-AA Phase 2a trial for severe or very severe alopecia areata and has received FDA Fast Track Designation for that indication. The company also maintains a tissue-targeted complement inhibition platform built around ADX-096 (a C3d–CR1 fusion protein) and earlier-stage C3d monoclonal antibody fusions and nanobodies, designed to localize complement inhibition to diseased tissue while preserving other complement functions. In December 2025, Q32 Bio divested its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million upfront plus up to $592 million in potential milestones and tiered royalties, refocusing resources on bempikibart.

Q32 Bio is publicly traded on Nasdaq (ticker: QTTB) following a March 2024 reverse merger with Homology Medicines and a concurrent $42 million private placement. The company is pre-revenue, with no approved products, and funds operations entirely through equity capital markets — having raised approximately $79.5 million in 2026 across a $10.5 million registered direct offering, $14.2 million and up to $75 million ATM programs with Cantor Fitzgerald, and a $55 million private placement led by BVF Partners L.P. with participation from RA Capital Management, OrbiMed, and Atlas Venture. Q1 2026 net loss was $7.6 million (reduced from $11.0 million in the prior-year period), and cash runway has been extended into 1H 2028. The company is led by CEO Jodie Morrison (former CEO of Cadent Therapeutics), CSO/President of Research Shelia Violette (Ph.D., ex-VP Research at Biogen), and President & CFO Lee Kalowski (former CFO of Bicycle Therapeutics). Future commercialization is expected to be enabled via out-licensing and strategic partnerships with larger pharmaceutical companies, as demonstrated by the Akebia transaction.

Q32 Bio firmographics

Firmographics
Name
Q32 Bio
Legal name
Q32 Bio Inc.
Website
https://q32bio.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Q32 Bio is a clinical-stage biotechnology company developing bempikibart, an anti-IL-7Rα monoclonal antibody in Phase 2a for severe alopecia areata, plus a tissue-targeted complement inhibition platform for patients with autoimmune and inflammatory diseases.
Ownership category
akta.pro rank

Q32 Bio industry classification

Industry
Product category
Biologics for Autoimmune Diseases
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Clinical-stage biotechnology
  • Autoimmune disease therapeutics
  • Monoclonal antibody development
  • Complement inhibition platform
  • Inflammatory disease treatments

Where Q32 Bio is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Q32 Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Out-licensing and asset divestiture: Pre-revenue clinical-stage biotech monetizing non-core assets via out-licensing/divestiture. Sold Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million upfront plus near-term milestone payments, up to $592 million in potential milestone payments, and tiered royalties. No product revenue is generated as bempikibart remains in clinical development.
  2. Equity / capital markets financing: Repeated capital raises via registered direct offerings, private placements, and at-the-market (ATM) equity programs to fund clinical development. 2024-2026 financings include a $42M private placement (with Homology merger), $10.5M direct offering, $14.2M ATM, and $55M private placement.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Q32 Bio product offering

Product offering

Core offering

Q32 Bio is a clinical-stage biotechnology company developing biologic therapies that rebalance the immune system in patients with severe autoimmune and inflammatory diseases. Its lead candidate, bempikibart (ADX-914), is a fully human anti–IL-7Rα monoclonal antibody currently in the SIGNAL-AA Phase 2a trial for severe or very severe alopecia areata, supported by FDA Fast Track Designation. The company also operates a tissue-targeted complement inhibition platform anchored by C3d–CR1 fusion proteins and nanobodies, with development candidate ADX-096.

Product overview

Q32 Bio is a clinical-stage biotechnology company with a focused, single-platform therapeutic portfolio rather than a software-style platform-plus-modules architecture. Its lead clinical asset, bempikibart (ADX-914), is a fully human anti-IL-7Rα monoclonal antibody that anchors the company's IL-7/TSLP program, currently in the SIGNAL-AA Phase 2a trial for severe or very severe alopecia areata. Complementing this is the Complement Inhibitor Platform — a tissue-targeted complement modulation platform built around the development candidate ADX-096 (a C3d–CR1 fusion protein) plus earlier-stage C3d mAb fusions and nanobodies, with the previously advanced ADX-097 divested to Akebia Therapeutics in 2025. Together, the IL-7/TSLP Program and the Complement Inhibitor Platform form the entirety of Q32 Bio's disclosed product offering, all aimed at restoring immune homeostasis in patients with severe inflammatory and autoimmune diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bempikibart (ADX-914) Bempikibart (ADX-914) is a fully human anti–interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling through their shared receptor. It is Q32 Bio's most advanced product candidate, currently in the SIGNAL-AA Phase 2a trial in patients with severe or very severe alopecia areata, and has received FDA Fast Track Designation for alopecia areata.
  • ADX-096 ADX-096 is a C3d–CR1 fusion protein and lead asset of Q32 Bio's tissue-targeted complement inhibitor platform. It is designed to deliver complement inhibition directly to diseased tissue while leaving other complement functions largely unimpaired, addressing complement-mediated diseases across kidney, skin, blood, lung, neuromuscular junction, and brain indications.
  • IL-7/TSLP Program The IL-7/TSLP program is Q32 Bio's research and clinical effort targeting dysfunctional regulation of the adaptive immune system by blocking IL-7 and TSLP signaling. Its lead clinical asset is bempikibart (ADX-914); the program is being evaluated in alopecia areata and explored for additional autoimmune and inflammatory indications where IL-7 and/or TSLP pathways drive disease.

Quantifiable outcome

  • SIGNAL-AA Phase 2a Part B enrolled 33 patients, exceeding the initial target of 20 patients
  • +4 more outcomes

Companies that use Q32 Bio

Customer profile

Segments3 records

Ideal customer profiles3 records

Q32 Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Q32 Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and major.

  • AmgenminorStrategic or Co-development Partner · 22 May 2026Q32 Bio amended its agreement with Amgen to eliminate $75.1 million in remaining regulatory and sales milestone obligations, removing a material contingent liability from the company's balance sheet.
  • Akebia TherapeuticsmajorStrategic or Co-development Partner · 1 December 2025Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, receiving $12 million upfront plus additional near-term milestone payments, up to $592 million in potential milestone payments, and tiered royalties. The transaction funds Q32 Bio's operations into 2027 and allows it to focus resources on bempikibart for alopecia areata.
  • Bristol Myers SquibbmajorOEM/ Whitelabel/ Licensing PartnerBristol Myers Squibb is the originator from which Q32 Bio licensed bempikibart. Q32 Bio retained global rights to develop and commercialize the asset, including the ongoing SIGNAL-AA Phase 2a program.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Q32 Bio competitors and assessment

Company assessment

Direct peers

  • Concert Pharmaceuticals: Clinical-stage biotech developing treatments for alopecia areata, including deuruxolitinib (a JAK inhibitor). Highly comparable as a similarly sized, single-indication-focused biotech pursuing severe alopecia areata with a novel mechanism.
  • Aclaris Therapeutics: Clinical-stage immunology-focused biotech developing therapies for alopecia areata and other inflammatory skin diseases. Directly comparable in target indication, development stage, and small-cap biotech profile.
  • AnaptysBio: Clinical-stage biotech developing antibodies targeting inflammatory and autoimmune pathways, including IL-36R antagonists. Comparable in therapeutic area (autoimmune/inflammatory biologics), clinical stage, and small-cap profile.

Broad incumbents

  • Horizon Therapeutics: Large immunology-focused biotech (now part of Amgen) that was previously partnered with Q32 Bio on bempikibart's Phase 2 study in atopic dermatitis. Comparable as a developer of immunology biologics with overlapping autoimmune disease focus.

Emerging players

  • Akebia Therapeutics: Biotech that acquired Q32 Bio's ADX-097 complement inhibitor and is developing it for complement-mediated diseases including renal diseases. Directly comparable as a small-cap clinical-stage biotech working in the complement pathway space.
  • Apogee Therapeutics: Clinical-stage biotech developing novel biologics for atopic dermatitis and other inflammatory diseases. Comparable as a recently public small-cap immunology biotech pursuing autoimmune indications with biologic modalities.
  • Dice Therapeutics: Clinical-stage biotech developing oral IL-17 inhibitors for autoimmune diseases (acquired by Eli Lilly in 2024). Comparable in therapeutic area, modality innovation, and clinical-stage development focus.
  • Cabaletta Bio: Clinical-stage biotech developing cell therapies for autoimmune diseases. Comparable as a small-cap clinical-stage immunology biotech with novel therapeutic modalities targeting autoimmune pathways.
  • Viridian Therapeutics: Clinical-stage biotech developing monoclonal antibodies for autoimmune diseases, including FcRn inhibitors. Comparable as a small/mid-cap clinical-stage immunology biotech with similar investor base (RA Capital, BVF, Atlas Venture participated in financings).

Others

  • Bristol Myers Squibb: Original licensor of bempikibart to Q32 Bio, retaining milestone/royalty rights. As a major pharma with JAK inhibitors and immunology franchises, BMS is both an asset licensor and a potential competitor/acquirer, making it a structural reference point.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Q32 Bio social profiles

Digital presence

Q32 Bio compliance and trust

Trust signal

Compliance1 record

Q32 Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Q32 Bio leadership team

Management profile

Number of profiles

Profiles9 records

Q32 Bio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Q32 Bio M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Q32 Bio

What does Q32 Bio do?

Q32 Bio is a clinical-stage biotechnology company developing biologic therapies that rebalance the immune system in patients with severe autoimmune and inflammatory diseases. Its lead candidate, bempikibart (ADX-914), is a fully human anti–IL-7Rα monoclonal antibody currently in the SIGNAL-AA Phase 2a trial for severe or very severe alopecia areata, supported by FDA Fast Track Designation. The company also operates a tissue-targeted complement inhibition platform anchored by C3d–CR1 fusion proteins and nanobodies, with development candidate ADX-096.

Is Q32 Bio a public or private company?

Q32 Bio is a public company. It is classified as public and is currently operating.

When was Q32 Bio founded?

Q32 Bio was founded in 2017. It employs 11 to 50 people.

Where is Q32 Bio based?

Q32 Bio is headquartered in Waltham, United States, in the North America region.

How does Q32 Bio make money?

Two revenue lines are on record. Out-licensing and asset divestiture is the primary driver. The others are equity / capital markets financing.

Who are Q32 Bio's main competitors?

Direct peers on record are Concert Pharmaceuticals, Aclaris Therapeutics and AnaptysBio. Horizon Therapeutics is listed as a broad incumbent. Emerging players are Akebia Therapeutics, Apogee Therapeutics, Dice Therapeutics, Cabaletta Bio and Viridian Therapeutics. Bristol Myers Squibb is listed as an others.

Does Q32 Bio have an API?

No public API is recorded for Q32 Bio.

What industry is Q32 Bio in?

Q32 Bio's product category is Biologics for Autoimmune Diseases. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comQ32 Bio at Jefferies Global Healthcare Conference: phase iii pushQ32 Bio said it will advance bempikibart into Phase III for alopecia areata after strong Phase II data, with an 850-patient trial expected to start in the first half of 2027. The company has just under $300 million in cash to fund the study and is negotiating final FDA alignment. It is also evaluating new indications, including vitiligo and rheumatoid arthritis.American Banking and Market NewsQ32 Bio (QTTB) Projected to Announce Earnings on ThursdayQ32 Bio is projected to report Q3 2026 earnings on Thursday, with analysts expecting a loss of $0.36 per share. The company's last quarterly EPS was -$0.26, beating the -$0.33 consensus, and revenue was $0.17 million. Analysts have set a consensus price target of $32.17.MarketBeatQ32 Bio Inc. (NASDAQ:QTTB) Stock Has Average Price Target of $32.17 According to AnalystsQ32 Bio Inc. has a consensus Moderate Buy rating with an average 12-month price target of $32.17. Analysts include HC Wainwright, Leerink Partners, and Mizuho, while insiders sold 22,054 shares in the last 90 days. Institutional investors own 31.32% of the stock.American Banking and Market NewsQ32 Bio Inc. (NASDAQ:QTTB) Stock Has Average Price Target of $32.17 According to AnalystsQ32 Bio shares have a consensus 'Moderate Buy' rating with an average 12-month price target of $32.17. Analysts include HC Wainwright, Leerink, and Mizuho, while insiders sold 22,054 shares in the last 90 days. The company reported a loss of $0.44 per share for the quarter.Ticker ReportHead to Head Review: Q32 Bio (NASDAQ:QTTB) vs. Applied Therapeutics (NASDAQ:APLT)Q32 Bio and Applied Therapeutics are compared on valuation, earnings, and analyst ratings. Q32 Bio has higher revenue and earnings, while Applied Therapeutics shows higher analyst upside. Q32 Bio beats Applied Therapeutics on 10 of 14 factors.American Banking and Market NewsFinancial Comparison: Applied Therapeutics (NASDAQ:APLT) and Q32 Bio (NASDAQ:QTTB)A comparison of Q32 Bio and Applied Therapeutics shows Q32 Bio outperforming on 10 of 14 factors, including higher revenue and earnings. Analysts rate Applied Therapeutics more favorably due to a higher potential upside of 870.87% versus Q32 Bio's 265.99%.American Banking and Market NewsQ32 Bio (NASDAQ:QTTB) Now Covered by Leerink PartnersLeerink Partners began coverage of Q32 Bio with an outperform rating and a $40 price target, implying 379.62% upside from the previous close. Other analysts also rated the stock, with an average rating of Moderate Buy and an average target of $32.17. The company reported a quarterly loss of $0.44 per share, beating estimates.Ticker ReportHead to Head Review: Kyntra Bio (NASDAQ:KYNB) and Q32 Bio (NASDAQ:QTTB)Kyntra Bio and Q32 Bio are compared across institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, and profitability. Kyntra Bio has a higher consensus target price and lower P/E ratio, while Q32 Bio beats on nine of fifteen factors. Analysts favor Kyntra Bio due to its higher probable upside.MarketBeatLeerink Partners Begins Coverage on Q32 Bio (NASDAQ:QTTB)Leerink Partners initiated coverage on Q32 Bio with an outperform rating and a $40 price target, implying 379.62% upside from the current price. The stock opened at $8.34, and analysts have an average rating of Moderate Buy with a $32.17 target. Q32 Bio reported a loss of $0.44 per share for the quarter, beating estimates.STATUp and down the ladder: The latest comings and goingsQ32 Bio hired José Trevejo as chief medical officer. He previously served as chief medical officer and head of clinical pipeline strategy at Enveda Therapeutics. The article is exclusive to STAT+ subscribers.